{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T17:28:08Z","timestamp":1793899688140,"version":"4.8.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:00:00Z","timestamp":1789776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:00:00Z","timestamp":1789776000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s00415-026-14140-1","type":"journal-article","created":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T17:30:34Z","timestamp":1789839034000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical trials in non-ambulatory people with progressive multiple sclerosis: can the nine hole peg test step up as primary outcome measure?"],"prefix":"10.1007","volume":"273","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4378-0089","authenticated-orcid":false,"given":"Miguel","family":"D\u2019Haeseleer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva M. M.","family":"Strijbis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Cutter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laetitia","family":"della Faille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie B.","family":"D\u2019hooghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daphne","family":"Kos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Lotte","family":"Lison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jop","family":"Mostert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Nagels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavle","family":"Repovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard M. J.","family":"Uitdehaag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Van Remoortel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen","family":"Van Schependom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus W.","family":"Koch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,19]]},"reference":[{"issue":"1","key":"14140_CR1","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/ene.13819","volume":"26","author":"R Dobson","year":"2019","unstructured":"Dobson R, Giovannoni G (2019) Multiple sclerosis - a review. Eur J Neurol 26(1):27\u201340. https:\/\/doi.org\/10.1111\/ene.13819","journal-title":"Eur J Neurol"},{"issue":"11","key":"14140_CR2","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1212\/wnl.33.11.1444","volume":"33","author":"JF Kurtzke","year":"1983","unstructured":"Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33(11):1444\u20131452. https:\/\/doi.org\/10.1212\/wnl.33.11.1444","journal-title":"Neurology"},{"issue":"4","key":"14140_CR3","doi-asserted-by":"publisher","first-page":"184","DOI":"10.7224\/1537-2073.2020-114","volume":"24","author":"B Weinstock-Guttman","year":"2022","unstructured":"Weinstock-Guttman B, Sormani MP, Repovic P (2022) Predicting long-term disability in multiple sclerosis: a narrative review of current evidence and future directions. Int J MS Care 24(4):184\u2013188. https:\/\/doi.org\/10.7224\/1537-2073.2020-114","journal-title":"Int J MS Care"},{"key":"14140_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2377-14-58","volume":"14","author":"S Meyer-Moock","year":"2014","unstructured":"Meyer-Moock S, Feng YS, Maeurer M, Dippel FW, Kohlmann T (2014) Systematic literature review and validity evaluation of the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC) in patients with multiple sclerosis. BMC Neurol 14:58. https:\/\/doi.org\/10.1186\/1471-2377-14-58","journal-title":"BMC Neurol"},{"issue":"5","key":"14140_CR5","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1177\/1352458517690824","volume":"23","author":"P Feys","year":"2017","unstructured":"Feys P, Lamers I, Francis G et al (2017) The nine-hole peg test as a manual dexterity performance measure for multiple sclerosis. Mult Scler 23(5):711\u2013720. https:\/\/doi.org\/10.1177\/1352458517690824","journal-title":"Mult Scler"},{"issue":"6","key":"14140_CR6","doi-asserted-by":"publisher","first-page":"386","DOI":"10.5014\/ajot.39.6.386","volume":"39","author":"V Mathiowetz","year":"1985","unstructured":"Mathiowetz V, Volland G, Kashman N, Weber K (1985) Adult norms for the Box and Block Test of manual dexterity. Am J Occup Ther 39(6):386\u2013391. https:\/\/doi.org\/10.5014\/ajot.39.6.386","journal-title":"Am J Occup Ther"},{"issue":"10","key":"14140_CR7","first-page":"850","volume":"69","author":"DE Goodkin","year":"1988","unstructured":"Goodkin DE, Hertsgaard D, Seminary J (1988) Upper extremity function in multiple sclerosis: improving assessment sensitivity with box-and-block and nine-hole peg tests. Arch Phys Med Rehabil 69(10):850\u2013854","journal-title":"Arch Phys Med Rehabil"},{"issue":"10","key":"14140_CR8","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000213558","volume":"104","author":"L Kappos","year":"2025","unstructured":"Kappos L, Yiu S, Dahlke F et al (2025) Composite confirmed disability worsening\/progression is a useful clinical endpoint for multiple sclerosis clinical trials. Neurology 104(10):e213558. https:\/\/doi.org\/10.1212\/WNL.0000000000213558","journal-title":"Neurology"},{"issue":"9","key":"14140_CR9","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.1111\/ene.15920","volume":"30","author":"MW Koch","year":"2023","unstructured":"Koch MW, Repovic P, Mostert J et al (2023) Threshold definitions for significant change on the timed 25-foot walk and nine-hole peg test in primary progressive multiple sclerosis. Eur J Neurol 30(9):2761\u20132768. https:\/\/doi.org\/10.1111\/ene.15920","journal-title":"Eur J Neurol"},{"key":"14140_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.104433","volume":"69","author":"MW Koch","year":"2023","unstructured":"Koch MW, Repovic P, Mostert J et al (2023) The nine hole peg test as an outcome measure in progressive MS trials. Mult Scler Relat Disord 69:104433. https:\/\/doi.org\/10.1016\/j.msard.2022.104433","journal-title":"Mult Scler Relat Disord"},{"key":"14140_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2025.1637835","volume":"16","author":"J Temmerman","year":"2025","unstructured":"Temmerman J, Vanremoortel A, Bjerke M et al (2025) Real-world brain volumetry in multiple sclerosis: importance of methodological consistency and clinical relevance of gray matter atrophy. Front Neurol 16:1637835. https:\/\/doi.org\/10.3389\/fneur.2025.1637835","journal-title":"Front Neurol"},{"key":"14140_CR12","volume-title":"R: a language and environment for statistical computing","author":"R Core Team","year":"2024","unstructured":"R Core Team (2024) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria"},{"issue":"13","key":"14140_CR13","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1177\/13524585251384060","volume":"31","author":"FB Briggs","year":"2025","unstructured":"Briggs FB, Yang J, Toljan K et al (2025) Longitudinal modeling of upper extremity function in multiple sclerosis: associations for clinical and sociodemographic factors. Mult Scler 31(13):1572\u20131582","journal-title":"Mult Scler"},{"issue":"3","key":"14140_CR14","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1606468","volume":"376","author":"X Montalban","year":"2017","unstructured":"Montalban X, Hauser SL, Kappos L et al (2017) Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med 376(3):209\u2013220. https:\/\/doi.org\/10.1056\/NEJMoa1606468","journal-title":"N Engl J Med"},{"issue":"10127","key":"14140_CR15","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/S0140-6736(18)30475-6","volume":"391","author":"L Kappos","year":"2018","unstructured":"Kappos L, Bar-Or A, Cree BAC et al (2018) Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet 391(10127):1263\u20131273. https:\/\/doi.org\/10.1016\/S0140-6736(18)30475-6","journal-title":"Lancet"},{"issue":"5","key":"14140_CR16","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1038\/nrneurol.2015.34","volume":"11","author":"MW Koch","year":"2015","unstructured":"Koch MW, Korngut L, Patry DG et al (2015) The promise of futility trials in neurological diseases. Nat Rev Neurol 11(5):300\u2013305. https:\/\/doi.org\/10.1038\/nrneurol.2015.34","journal-title":"Nat Rev Neurol"},{"issue":"3","key":"14140_CR17","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/S1474-4422(24)00027-9","volume":"23","author":"J Chataway","year":"2024","unstructured":"Chataway J, Williams T, Li V, Marrie RA, Ontaneda D, Fox RJ (2024) Clinical trials for progressive multiple sclerosis: progress, new lessons learned, and remaining challenges. Lancet Neurol 23(3):277\u2013301. https:\/\/doi.org\/10.1016\/S1474-4422(24)00027-9","journal-title":"Lancet Neurol"},{"issue":"9","key":"14140_CR18","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1177\/13524585231189671","volume":"29","author":"RA Marrie","year":"2023","unstructured":"Marrie RA, Sormani MP, Apap Mangion S et al (2023) Improving the efficiency of clinical trials in multiple sclerosis. Mult Scler 29(9):1136\u20131148. https:\/\/doi.org\/10.1177\/13524585231189671","journal-title":"Mult Scler"},{"issue":"5","key":"14140_CR19","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1212\/01.wnl.0000201252.57661.e1","volume":"66","author":"NN-P Investigators","year":"2006","unstructured":"NN-P Investigators (2006) A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology 66(5):664\u2013671. https:\/\/doi.org\/10.1212\/01.wnl.0000201252.57661.e1","journal-title":"Neurology"},{"issue":"6","key":"14140_CR20","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1002\/ana.26239","volume":"90","author":"MW Koch","year":"2021","unstructured":"Koch MW, Kaur S, Sage K et al (2021) Hydroxychloroquine for primary progressive multiple sclerosis. Ann Neurol 90(6):940\u2013948. https:\/\/doi.org\/10.1002\/ana.26239","journal-title":"Ann Neurol"},{"issue":"1","key":"14140_CR21","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/ana.21079","volume":"61","author":"JS Wolinsky","year":"2007","unstructured":"Wolinsky JS, Narayana PA, O\u2019Connor P et al (2007) Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol 61(1):14\u201324. https:\/\/doi.org\/10.1002\/ana.21079","journal-title":"Ann Neurol"},{"issue":"10544","key":"14140_CR22","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1016\/S0140-6736(26)00617-3","volume":"407","author":"G Giovannoni","year":"2026","unstructured":"Giovannoni G, Airas L, Bove R et al (2026) Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis, including older patients and those with more advanced disease (ORATORIO-HAND): a multicentre, double-blind, randomised, placebo-controlled, phase 3b study. Lancet 407(10544):2195\u20132207. https:\/\/doi.org\/10.1016\/S0140-6736(26)00617-3","journal-title":"Lancet"},{"issue":"4","key":"14140_CR23","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1212\/CPJ.0000000000001045","volume":"11","author":"TL Vollmer","year":"2021","unstructured":"Vollmer TL, Nair KV, Williams IM, Alvarez E (2021) Multiple sclerosis phenotypes as a continuum: the role of neurologic reserve. Neurol Clin Pract 11(4):342\u2013351. https:\/\/doi.org\/10.1212\/CPJ.0000000000001045","journal-title":"Neurol Clin Pract"},{"issue":"1","key":"14140_CR24","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/S1474-4422(22)00289-7","volume":"22","author":"T Kuhlmann","year":"2023","unstructured":"Kuhlmann T, Moccia M, Coetzee T et al (2023) Multiple sclerosis progression: time for a new mechanism-driven framework. Lancet Neurol 22(1):78\u201388. https:\/\/doi.org\/10.1016\/S1474-4422(22)00289-7","journal-title":"Lancet Neurol"},{"issue":"10","key":"14140_CR25","doi-asserted-by":"publisher","first-page":"3414","DOI":"10.1038\/s41591-025-03901-6","volume":"31","author":"H Ganjgahi","year":"2025","unstructured":"Ganjgahi H, Haring DA, Aarden P et al (2025) AI-driven reclassification of multiple sclerosis progression. Nat Med 31(10):3414\u20133424. https:\/\/doi.org\/10.1038\/s41591-025-03901-6","journal-title":"Nat Med"},{"issue":"5","key":"14140_CR26","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1002\/ana.24497","volume":"78","author":"JM Frischer","year":"2015","unstructured":"Frischer JM, Weigand SD, Guo Y et al (2015) Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque. Ann Neurol 78(5):710\u2013721. https:\/\/doi.org\/10.1002\/ana.24497","journal-title":"Ann Neurol"},{"issue":"11","key":"14140_CR27","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/nrneurol.2012.168","volume":"8","author":"H Lassmann","year":"2012","unstructured":"Lassmann H, van Horssen J, Mahad D (2012) Progressive multiple sclerosis: pathology and pathogenesis. Nat Rev Neurol 8(11):647\u2013656. https:\/\/doi.org\/10.1038\/nrneurol.2012.168","journal-title":"Nat Rev Neurol"},{"key":"14140_CR28","doi-asserted-by":"publisher","DOI":"10.1177\/17562864211066751","volume":"15","author":"G Giovannoni","year":"2022","unstructured":"Giovannoni G, Popescu V, Wuerfel J et al (2022) Smouldering multiple sclerosis: the \u201creal MS.\u201d Ther Adv Neurol Disord 15:17562864211066751. https:\/\/doi.org\/10.1177\/17562864211066751","journal-title":"Ther Adv Neurol Disord"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-14140-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-026-14140-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-14140-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T17:04:13Z","timestamp":1793898253000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-026-14140-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,19]]},"references-count":28,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["14140"],"URL":"https:\/\/doi.org\/10.1007\/s00415-026-14140-1","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,19]]},"assertion":[{"value":"17 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Prof. D\u2019Haeseleer has received consultancy honoraria, educational support, research grants and\/or speaker fees from Merck-Serono, Bayer, Teva, Biogen, Sanofi-Genzyme, Novartis, Roche, Almirall, Janssen-Cilag, Bristol-Myers Squibb, Neuraxpharm, Amgen and UCB. Dr. Strijbis serves on the editorial board of Neurology and Frontiers in Neurology, and received speaker fees from Merck and Novartis. Prof. Cutter participated in Data and Safety Monitoring Boards for the following companies: Applied Therapeutics, AI Therapeutics, AMO Pharma, Astra-Zeneca, Avexis Pharmaceuticals, Bristol Meyers Squibb\/Celgene, CSL Behring, Cynata Therapeutics, Horizon Pharmaceuticals, Immunic, Karuna Therapeutics, Kezar Life Sciences, Mapi Pharmaceuticals Ltd, Merck, Mitsubishi Tanabe Pharma Holdings, Opko Biologics, Prothena Biosciences, Novartis, Pipeline Therapeutics, Regeneron, Sanofi-Aventis, Reata Pharmaceuticals, Teva Pharmaceuticals, United BioSource LLC, University of Texas Southwestern, University of Pennsylvania, and Visioneering Technologies, Inc.; participated in consulting or advisory boards of the following companies: Alexion, Antisense Therapeutics, Avotres, Biogen, Clene Nanomedicine, Clinical Trial Solutions LLC, Endra Life Sciences, Cognito Therapeutics, Entelexo Biotherapeutics, Inc., Genzyme, Genentech, GW Pharmaceuticals, Hoya Corporation, Immunic, Immunosis Pty Ltd, Klein-Buendel Incorporated, Linical, Merck\/Serono, Novartis, Perception Neurosciences, Protalix Biotherapeutics, Regeneron, Roche, SAB Biotherapeutics, and Sapience Therapeutics; is employed by the University of Alabama at Birmingham and is the president of Pythagoras, Inc., a private consulting company located in Birmingham, AL, USA. Dr. Della Faille has received consultancy honoraria, speaker fees, and travel support form Merck-Serono, Novartis, Sanofi-Genzyme, Roche, and EG. Prof. D\u2019hooghe has no relevant conflicts of interest to report. Prof. Kos has no relevant conflicts of interest to report. Dr. Lison has no relevant conflicts of interest to report. Dr. Mostert has no relevant conflicts of interest to report. Prof. Nagels benefits from a senior clinical research fellowship of the FWO Flanders (1805625N). Dr. Repovic has no relevant conflicts of interest to report. Prof. Uitdehaag received consultancy fees from Immunic Therapeutics (adjudication Committee, payment to the institute). Mrs. Van Remoortel has no relevant conflicts of interest to report. Prof. Van Schependom has no relevant conflicts of interest to report. Prof. Koch received consulting fees and travel support from Novartis.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval for this study was sought and granted by the ethics committees of the NMSC Melsbroek (institutional authorization number: OG 033; internal reference number: EC25\/12). The study was conducted in accordance with the guidelines and regulations of the approving ethics committee and the principles of the 1964 Declaration of Helsinki and its later amendments. According to the Belgian law, participant consent is not required for retrospective studies.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"608"}}